• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Most U.S. Patients are Likely to Find a Match for Hematopoietic Stem-Cell Transplants

August 15, 2014

tx_news_15_augustHematopoietic stem-cell transplants (HSCT) from either cord blood or adult volunteer donors are often used to treat patients with blood or bone marrow cancers.

The success of unrelated-donor HSCT transplants is dependent upon human leukocyte antigen (HLA) matching. Researchers from the National Marrow Donor Program recently determined the likelihood of finding a suitable unrelated-donor for 21 different ethnic groups in the U.S. registry, which contains over 10 million adult donors and more than 186,000 cord-blood units. Patient ethnicity significantly influenced whether a suitable adult donor or cord blood unit could be matched. Patients of white European ancestry have the best likelihood (75%) of finding a perfect HLA-matched adult donor, while black Americans have the worst likelihood (16-19%). In addition, because the registry contains fewer cord blood units, the likelihood of finding a perfect match is lower. Although most HSCT patients will be able to find an acceptable match, continued research will improve outcomes for HLA-mismatched grafts.

Reference
1. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D, Maiers M. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014;371: 339-48.

Filed Under

  • Cell Therapy
  • News

Recommended

  • Global Blood Supply Challenges

  • MiPLATE Clinical Trial: Mirasol® Pathogen Reduction Treated Platelets

  • FDA Approves Blood Tracking Device

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley